Welcome: Guest | Site Use Options | Register | Login |

Galenea Corporation

Galenea Corporation

Profile last edited on: 4/5/2019
50C Audubon Road
Wakefield, MA 01880
  (617) 374-1010
Business Identifier: Synaptic transmission (ST): process by which neurons communicate with each other
Public Profile:
Galenea Corporation is focused on developing drugs that treat neurodegenerative central neurvous system (CNS) diseases via the modulation of synaptic transmission: the process by which neurons communicate. The company uses an integrated drug discovery approach that utilizes its proprietary Multiwell Automated NeuroTRansmission Assay (MANTA) synaptic screening technology for primary neurons and neurons developed from human stem cells. The company is also focused on preclinical network measures based on MANTRA screening and is developing clinical biomarkers based on brain activity in humans as measured by electroencephalogram (EEG) for use in clinical development. Intitially based on research on the role of calcineurin in the pathogenisis of schizophrenia, the companny's discovery platform also generated a therapeutics program for cognitive impairment, and discovery programs in Huntington's disease and neurodegeneration.

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options


Is this YOUR Company?

Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached

Do you know about this Awardees?

Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920